Cargando…

RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers

BACKGROUND: The overall response rate to checkpoint blockade remains unsatisfactory, partially due to the immune-suppressive tumor microenvironment. A retinoic acid-related orphan receptor γt (RORγt) agonist (LYC-55716) is currently used in clinical trials combined with anti-PD-1, but how the Th17 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Li, Tian, Enming, Yu, Mingcheng, Liu, Chenglong, Shen, Lian, Huang, Yafei, Wu, Zhongen, Tian, Jinlong, Yu, Ker, Wang, Yonghui, Xie, Qiong, Zhu, Di
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034499/ https://www.ncbi.nlm.nih.gov/pubmed/35459193 http://dx.doi.org/10.1186/s13046-022-02289-2

Ejemplares similares

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation
por: Sun, Nannan, et al.
Publicado: (2018)

Ontogeny of RORγt(+) cells in the intestine of newborns and its role in the development of experimental necrotizing enterocolitis
por: Zhao, Xiuhao, et al.
Publicado: (2022)

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity
por: Hu, Xiao, et al.
Publicado: (2016)

HDX-MS reveals structural determinants for RORγ hyperactivation by synthetic agonists
por: Strutzenberg, Timothy S, et al.
Publicado: (2019)

Elucidation of an Allosteric Mode of Action for a Thienopyrazole RORγt Inverse Agonist
por: de Vries, Rens M. J. M., et al.
Publicado: (2020)

BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer
por: Feng, Mei, et al.
Publicado: (2021)

The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism
por: Wang, Yongjun, et al.
Publicado: (2015)

Correction: HDX-MS reveals structural determinants for RORγ hyperactivation by synthetic agonists
por: Strutzenberg, Timothy S, et al.
Publicado: (2019)

RORγt and RORα signature genes in human Th17 cells
por: Castro, Glenda, et al.
Publicado: (2017)

The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis
por: Ruan, Qingguo, et al.
Publicado: (2011)

The application of machine learning methods to the prediction of novel ligands for RORγ/RORγT receptors
por: Bachorz, Rafał A., et al.
Publicado: (2023)

Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach
por: Hu, Xiao, et al.
Publicado: (2014)

Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
por: Meijer, Femke A., et al.
Publicado: (2019)

CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis
por: Gouwy, Mieke, et al.
Publicado: (2016)

RORα and RORγ expression inversely correlates with human melanoma progression
por: Brożyna, Anna A., et al.
Publicado: (2016)

RORγ Structural Plasticity and Druggability
por: Huang, Mian, et al.
Publicado: (2020)

CXCL4 suppresses tolerogenic immune signature of monocyte‐derived dendritic cells
por: Silva‐Cardoso, Sandra C., et al.
Publicado: (2020)

Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
por: Fiorillo, Bianca, et al.
Publicado: (2023)

Essential functions of Runx/Cbfβ in gut conventional dendritic cells for priming Rorγt(+) T cells
por: Tenno, Mari, et al.
Publicado: (2019)

Silencing RORγt in Human CD4(+) T cells with CD30 aptamer-RORγt shRNA Chimera
por: Shi, Xiaofei, et al.
Publicado: (2019)

Identification of the Natural Steroid Sapogenin Diosgenin as a Direct Dual-Specific RORα/γ Inverse Agonist
por: Schwarz, Patrik F., et al.
Publicado: (2022)

Correction to “Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders”
por: Fiorillo, Bianca, et al.
Publicado: (2023)

CXCL4 Links Inflammation and Fibrosis by Reprogramming Monocyte-Derived Dendritic Cells in vitro
por: Silva-Cardoso, Sandra C., et al.
Publicado: (2020)

CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration
por: Fox, James M., et al.
Publicado: (2018)

Splenic differentiation and emergence of CCR5(+)CXCL9(+)CXCL10(+) monocyte-derived dendritic cells in the brain during cerebral malaria
por: Hirako, Isabella C., et al.
Publicado: (2016)

Identification of an allosteric binding site for RORγt inhibition
por: Scheepstra, Marcel, et al.
Publicado: (2015)

Regulation of p53 Stability and Apoptosis by a ROR Agonist
por: Wang, Yongjun, et al.
Publicado: (2012)

Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome
por: Caldarale, Francesca, et al.
Publicado: (2021)

CXCL1 Contributes to β-Amyloid-Induced Transendothelial Migration of Monocytes in Alzheimer’s Disease
por: Zhang, Ke, et al.
Publicado: (2013)

The therapeutic potential of RORγ modulators in the treatment of human disease
por: Chang, Mi Ra, et al.
Publicado: (2012)

Effects of RORγt overexpression on the murine central nervous system
por: Sasaki, Tetsuya, et al.
Publicado: (2021)

RORγt phosphorylation protects against T cell-mediated inflammation
por: Ma, Shengyun, et al.
Publicado: (2022)

Identification of RORγ as a favorable biomarker for colon cancer
por: Pan, Xiaofei, et al.
Publicado: (2021)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

An inhibitor of RORγ for chronic pulmonary obstructive disease treatment
por: Desai, Harshada, et al.
Publicado: (2022)

RORγt expression in mature T(H)17 cells safeguards their lineage specification by inhibiting conversion to T(H)2 cells
por: Chi, Xinxin, et al.
Publicado: (2022)

Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients
por: Carvalheiro, Tiago, et al.
Publicado: (2017)

Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds
por: Ding, Qingfeng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b8ok50qgr6huscb0cqhb9gl71c